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Tamoxifen is the current therapy of choice for patients with oestrogen receptor positive breast cancer, and it is currently
under evaluation as a prophylactic for women at high risk of developing the disease. However, tamoxifen is also known to
induce proliferative changes in the endometrium increasing the risk of developing endometrial hyperplasia, polyps and
carcinoma. Angiogenesis is an intimate part of this process. For this reason, we have examined the expression of several well
characterized angiogenic factors, namely, acidic and basic ﬁbroblast growth factor, thymidine phosphorylase, vascular
endothelial growth factor and adrenomedullin in both normal and tamoxifen exposed pre- and postmenopausal endometrium.
Vascular density and endothelial proliferation index were also quantiﬁed. We found increased expression of acidic and basic
ﬁbroblast growth factor and adrenomedullin after treatment with tamoxifen mainly in premenopausal tissue. Vascular density
was signiﬁcantly increased in pre- but not post-menopausal endometrium (P=0.0018) following tamoxifen treatment. These
results support the notion that angiogenesis is integral to the response to tamoxifen exposure, and is a potential target with
which to block these side effects of tamoxifen.
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The non-steriodal anti-oestrogen tamoxifen (TAM) is currently the
long-term treatment of choice for selected patients with breast
cancer, since large clinical trials have shown reduction in recur-
rence and overall survival beneﬁt. Tamoxifen is currently being
evaluated as a chemopreventative agent in healthy women at risk
from the disease (Cuzick, 2000; Dalton and Kallab, 2001). One
of the most signiﬁcant complications of long-term TAM use is
the development of endometrial cancer with up to a 7.5-fold
increase in risk (Bergman et al, 2000; Carthew et al, 2000; Mourits
et al, 2001). The increasing use of TAM, especially in healthy young
subjects with no history of cancer, means that it is essential to
improve our understanding of the mechanisms by which it exerts
its adverse endometrial effects.
We have previously shown by differential PCR display that TAM,
but not oestrogen induces expression of adrenomedullin (ADM) in
endometrial isolates (Zhao et al, 1998). ADM stimulates angiogenesis
in the chick chorioallantoic membrane assay (Zhao et al, 1998). ADM
is also an autocrine growth factor for human endometrial endothelial
cells and is clearly involved in endometrial angiogenesis (Nikitenko et
al, 2000). ADM is pro-tumourigenic not solely due to its angiogenic
activity but also because it enhances carcinoma cell survival under
hypoxia by upregulation of Bcl2 (Oehler et al, 2001). ADM expres-
sion has been noted in a number of carcinomas (Hinson et al, 2000).
Other angiogenic factors which have been identiﬁed in endome-
trium, include vascular endothelial growth factor (VEGF) (Shifren
et al, 1996; Zhang et al, 1998), thymidine phosphorylase (TP)
(Zhang et al, 1997; Sivridis et al, 2000), basic ﬁbroblast growth
factor (bFGF) and acidic ﬁbroblast growth factor (aFGF) (Ferriani
et al, 1993). Vascular endothelial growth factor is now known to be
a key regulator in neoplastic angiogenesis and its expression is
upregulated in most human tumours (Ferrara and Davis-Smyth,
1997). Its expression is increased in human endometrial carcinoma
(Doldi et al, 1996; Zhang et al, 1998).
The expression of thymidine phosphorylase is well documented
in a number of carcinoma types (Brown and Bicknell, 1998) and
has been previously documented in human endometrium (Zhang
et al, 1997). It is also found in both simple and complex endome-
trial hyperplasias (Sivridis et al, 2000) but reports in human
endometrial cancer are conﬂicting (Zhang et al, 1997; Fujiwaki et
al, 1998; Sivridis et al, 1999). Increased expression of bFGF in
endometrial hyperplasia has been documented (Gold et al, 1994).
We are not aware of alteration of aFGF expression in endometrial
carcinomas apart from carcinoma lines (Fujimoto et al, 1997).
The aim of the study was to determine whether TAM therapy
changed the expression of a number of angiogenic factors in the
endometrium in the absence of neoplastic change. Vascular density
and endothelial proliferation index in normal and tamoxifen
exposed endometrial samples were also documented.
MATERIALS AND METHODS
Preparation of tissue
Formalin ﬁxed, wax embedded specimens of endometrium were
obtained from hysterectomy samples selected from the archival ﬁles
of the Histopathology Department of the John Radcliffe Hospital
(Oxford, UK). Thirty normal premenopausal hysterectomy samples
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www.bjcancer.comsubjective complaint of menorrhagia. No pelvic pathology was seen
at operation. This was conﬁrmed by a subsequent histological
examination by an independent histopathologist. All patients had
a history of regular 26–30 day menstrual cycles and had not used
oral or intrauterine contraception, nor taken any hormones for at
least 6 months prior to surgery. The stage of the menstrual cycle at
which the tissue was obtained was determined from the patients
menstrual history and endometrial histology (10=menstrual,
10=proliferative, 10=secretory) (Wells, 1996). In addition, 10 post-
menopausal normal endometrial samples were obtained from
women (aged 59–84) undergoing hysterectomy for uterovaginal
prolapse. Again no pelvic pathology was evident and the women
had not taken any hormones for at least 6 months. None of the
controls had ever received tamoxifen.
Eight premenopausal hysterectomy samples (ﬁve proliferative,
three secretory) and 13 postmenopausal hysterectomy samples
derived from women who were treated with TAM (for between 3–
5 years) were again obtained from the Histopathology Department
of the John Radcliffe Hospital. The indication for hysterectomy was
uterovaginal prolapse. The TAM exposed endometrial samples were
neither malignant or hyperplastic nor did they contain polyps and
were all the samples available collected over a 5 year time course.
All tissues were collected in accordance with the Central Oxford
Regional Ethics Committee (COREC C2519).
Immunohistochemistry
Immunohistochemistry was essentially as previously described
(Hague et al, 2000) brieﬂy, all sections were dewaxed using Citro-
clear (HS Supplies, Aylesbury, UK), rehydrated sequentially in
absolute, 95%, 70%, 20% ethanol, distilled water and ﬁnally rinsed
in TBS (pH 7.6) prior to staining.
aFGF and bFGF immunohistochemical staining
Immunohistochemical staining for aFGF was undertaken using the
streptavidin-biotin peroxidase (ABC) method using the VECTAS-
TAIN ABC kit for peroxidase (rabbit IgG) (Vector laboratories,
Burlingame, USA) according to the manufacturer’s protocol with
rabbit anti-bovine aFGF polyclonal antibody (Sigma, Poole, Dorset,
UK) at a dilution of 1 out of 200 in TBS/20% swine serum (SS).
Sections were washed in TBS twice, and then developed with
diaminobenzidine tetrahydrochloride (DAB) (Dako, Cambridge-
shire, UK). Immunohistochemistry of bFGF used the same
method with rabbit anti-bovine bFGF polyclonal antibody (Sigma,
UK) diluted to 84 ng ml
71 in TBS.
TP immunohistochemical staining
Immunohistochemical staining for TP was carried out using the
streptavidin-biotin-alkaline phosphatase (ABC) method. Prior to
application of the primary antibody, the sections were incubated
with 20% normal rabbit serum (NRS) to block non-speciﬁc protein
binding sites. Primary antibody, PGF44C (ICRF, UK) was added to
the slides for 30 min. The slides were then washed twice in TBS
and incubated for a further 30 min with biotinylated rabbit anti-
mouse immunoglobulin at a 1 out of 50 dilution. The sections
were washed again in TBS and incubated with streptavidin 1 out
of 200 (Dako) for 30 min. Chromogen development was
performed using a ‘New Fuchsin’ Substrate System (Dako) accord-
ing to the manufacturers instructions by incubation for 5–10 min.
Slides were counter stained with haematoxylin and mounted with
Apathy’s mounting medium
VEGF immunohistochemical staining
Immunohistochemical staining for VEGF was carried out using the
streptavidin-biotin-alkaline phosphatase (ABC) method, as
previously described (Zhang et al, 1998). The ‘New Fuchsin’
Substrate System was used to visualise the sections. In the negative
controls the primary antibodies were replaced with the same
subtype of mouse immunoglubin (Sigma) at the same concentra-
tion.
Adrenomedullin immunohistochemical staining
Immunohistochemistry was carried out as previously described
(Zhao et al, 1998). Brieﬂy, slides were incubated with 5% goat
serum (Dako) to reduce non-speciﬁc background staining,
followed by 1 out of 800 anti-adrenomedullin (Peninsula Labora-
tories, Liverpool, UK). A second biotinylated swine anti-rabbit
antibody (Dako) at a dilution of 1 out of 400 was then applied
for 30 min after which the slides were incubated with streptavidin
1 out of 200 (Dako) for 30 min, the ﬁnal colour being developed
with the ‘New Fuschin’ substrate system (Dako).
Ki67/CD34 double staining
Immunohistochemical staining for CD34 was performed using the
streptavidin-biotin-alkaline phosphatase (ABC) method. Through-
out the protocol all antibody dilutions and washes were
performed in TBS, with all incubations being performed at room
temperature. Antigen retrieval was performed by means of pressure
cooking in 1.6 l 0.01 M sodium citrate buffer (pH 6.0) for 90 s,
followed by a 30 min rinse in distilled water and 5 min in TBS.
Prior to the application of the primary antibody the sections were
blocked in 10% normal human serum. The sections were incubated
at room temperature for 30 min with the primary CD34 antibody
(Qbend 10, Novacastra, Newcastle upon Tyne, UK), diluted 1:25.
Again the sections were rinsed for 265 min, followed by a 30 min
incubation with the secondary biotinylated rabbit anti mouse IgG
(Sigma), diluted 1:400. The sections were incubated with phos-
phate conjugated streptavidin at a dilution of 1:200 for 30 min.
The ﬁnal colour was developed with the New Fuschin substrate
(Dako).
The Vectastain ABC kit was utilised for the staining of Ki67.
Prior to staining, double stain enhancer (Zymed, San Francisco,
CA, USA) was added to the sections; endogenous peroxidase activ-
ity was quenched by the application of 0.3% hydrogen peroxide,
diluted in distilled water. The sections were washed, and incubated
in horse serum, after which the primary Ki 67 (Bio Genex, San
Ramon, CA, USA) antibody at a dilution of 1 out of 10 was added
for 30 min. The sections were washed and incubated with the
secondary biotinylated ABC antibody for 30 min, with the ﬁnal
colour being developed with DAB substrate (Sigma, UK).
Scoring of immunohistochemical staining
The staining for aFGF, bFGF, TP, VEGF and ADM was scored on a
scale of 1–3+, with 3+ indicating a strong positive result. The
stroma, epithelium and endothelium were scored separately.
Sections were examined by two reviewers (S Hague and S Manek).
The ﬁnal score, averaged across each section, was agreed upon by
the two examiners.
Determination of vascular density and endothelial cell
proliferative indices
Vascular density was determined by Chalkley counting in three areas
selected at random (Fox et al, 1995). Vessels were counted using a 25-
point Chalkley eyepiece graticule at magniﬁcation 6250. The grati-
cule was rotated in the eyepiece to where the maximal number of
vessels were overlaid by graticule dots. Individual density was then
obtained by taking the mean of three graticule counts.
The endothelial cell proliferative index was determined at 6400
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nuclei that also had concomitant positive cytoplasmic staining in
CD34 positive cells
Statistical analysis
Analysis of microvascular density, the endothelial cell proliferation




Negative or very weak aFGF expression was detected in normal
endometrium, localising predominantly to the glandular epithe-
lium, stroma and endothelium of the blood vessels (Figure 1A).
No change in the expression level of aFGF was observed through
the menstrual cycle. In postmenopausal endometrial tissue, aFGF
localised to the stroma, glandular epithelium and blood vessels in
the control group (Figure 1B). The intensity of staining for aFGF
expression in normal premenopausal and postmenopausal endome-
trium was compared (Table 1). Menopausal status did not
signiﬁcantly alter aFGF expression.
Expression of aFGF in the TAM exposed premenopausal endo-
metrium was observed predominantly in the stroma and at a
reduced level in the epithelium (Figure 1C). A comparison of the
level of stain intensity between the premenopausal TAM exposed
endometrium and the normal controls revealed that the level of
aFGF staining was signiﬁcantly higher in the glandular epithelium
(P=0.001) stroma (P=0.0097), and in the blood vessels (P=0.0117)
(Figure 1A compared to Figure 1C).
In the postmenopausal TAM exposed endometrial tissue, aFGF
localized again to the stroma, glandular epithelium and blood vessels
(Figure 1D). Comparison of the intensity of staining revealed no
signiﬁcant differences between the control and TAM exposed post-
menopausal tissue (Figure 1B compared to Figure 1D). The
staining intensity was higher in the premenopausal than in the post-
menopausal TAM exposed tissue but did not achieve signiﬁcance.
bFGF
Unlike aFGF, expression of bFGF was observed in all of the normal

































Figure 1 Localization of aFGF in the endometrium using a streptABC alkaline phosphatase method. Positive staining appears red. (A) Weak expression in
the normal endometrium (early secretory), (B) weak aFGF expression in the epithelium and stroma of the post menopausal endometrium, (C) increased
expression in the epithelium and stroma of the premenopausal tamoxifen samples (early proliferative). (D) weak expression in the epithelium and stroma of
the post menopausal tamoxifen exposed endometrium (Magniﬁcation 6400) (Arrowhead indicates position of a blood vessel).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 761–767glandular epithelium and at a greatly reduced level, in the stroma
and endothelium (Figure 2A). Expression of bFGF increased in the
proliferative phase and was reduced in the secretory phase of the
menstrual cycle. In the postmenopausal control group, bFGF stain-
ing was observed in the epithelium, stroma and endothelium of the
blood vessels (Figure 2B). The level was lower than that seen in the
premenopausal control tissue. Statistical comparison, of bFGF
intensity between pre and postmenopausal normal endometrium,
showed that the level of expression was signiﬁcantly higher in
premenopausal glandular epithelial tissue (P=0.0005) and in the
blood vessels (P=0.0142) but not in the stroma
Expression of bFGF in the endometrium of premenopausal
TAM treated patients was evident in the stroma and epithelium,
staining with approximately equal intensities, in contrast to the
control group (Figure 2C). The intensity of staining remained
constant during the cycle. The level of bFGF staining was signiﬁ-
cantly higher in the stroma (P=0.024) of the TAM exposed
tissues, but not in the epithelium or endothelium (Figure 2A
compared to Figure 2C).
Expression of bFGF was observed in the stroma, epithelium and
blood vessels of the postmenopausal TAM exposed endometrium
(Figure 2D). The level of expression in the epithelium of the
TAM exposed tissue was signiﬁcantly higher (P=0.0021) than that
in the postmenopausal controls (Figure 2B compared to Figure
2D). Comparison of the staining intensities between the pre and
postmenopausal TAM exposed endometrium, showed no signiﬁ-
cant difference.
Thymidine phosphorylase (TP)
TP was detected in the control premenopausal endometrium
throughout the menstrual cycle. Immunostaining was most intense
in the glandular epithelium of the late secretory and menstrual
phases. Staining of the endometrial stroma and endothelium was
present at a lower level. TP expression was not detected. in the
postmenopausal endometrium.
TP expression in the endometrium of premenopausal women
exposed to TAM was evident in both the stroma and glandular
epithelium. The degree of cyclical change in TP expression was
not as apparent as in the normal premenopausal endometrium.
No signiﬁcant differences in the level of stain intensity for TP
between the premenopausal TAM and control groups was found.
Several of the postmenopausal TAM exposed endometrial
samples exhibited TP expression in the stroma and epithelium,
however the majority of the samples did not. No statistical differ-
ences were observed in the expression level of TP in the
postmenopausal controls and TAM exposed samples. While the
level of staining intensity was higher in pre than in postmenopausal
TAM exposed tissue, this did not achieve statistical signiﬁcance.
VEGF
VEGF was present in the endometrium of the control samples
throughout the menstrual cycle and showed menstrual cycle-related
expression in the specimens examined. It was principally detected
in the glandular epithelium and at a reduced level in the stroma.
As previously reported (Zhang et al, 1998), the highest level of
staining was seen in the menstrual, early proliferative and late
secretory phases of the cycle. Moderate staining of the small blood
vessels was also observed with the endothelial component staining
positive for the presence of VEGF. VEGF expression was primarily
observed in the glandular epithelium of normal postmenopausal
endometrium. VEGF expression was signiﬁcantly increased in
normal premenopausal tissue; epithelium (P50.001), stroma
(P=0.004), blood vessels (P=0.004).
Unlike the controls, VEGF expression was detected only in the
epithelium of the TAM exposed endometrium. Its expression did not
appear to alter with respect to the stage of the menstrual cycle and
was not signiﬁcantly increased. The TAM exposed postmenopausal
tissues exhibited VEGF expression in the epithelium and occasionally
in the stroma. There was no signiﬁcant difference in expression levels
between the postmenopausal controls and TAM exposed tissue.
When analysed according to menopausal status VEGF was
signiﬁcantly increased in pre- vs postmenopausal endometrium,
with the premenopausal tissue exhibiting a signiﬁcantly higher level
of expression in the epithelium (P=0.033) but not in the stroma or
the blood vessels.
ADM
The stroma, epithelium, endothelium and macrophages of the
normal premenopausal endometrium stained positive for ADM.
The staining was present throughout the menstrual cycle, with no
cycle speciﬁc change of expression. In the postmenopausal control
samples, ADM expression was observed in the epithelium and stro-
ma. Comparison of the expression levels between the control pre-
and postmenopausal endometrium showed no statistically signiﬁcant
difference in the level of expression of ADM in the epithelium, stroma
or blood vessel components of the endometrium.
Stroma, epithelium, endothelium and macrophages again stained
positive for the presence of adrenomedullin, in the TAM exposed
endometrium. In premenopausal tissues, TAM exposure signiﬁ-
cantly increased the level of staining in the stroma (P=0.00841)
compared to the controls. No signiﬁcant change was seen in the
epithelium or the endothelium of blood vessels.
In postmenopausal TAM exposed endometrium, ADM expres-
sion was observed in the epithelium and stroma. Statistical
analysis of the level of expression between the postmenopausal
normal and TAM exposed tissue, revealed no signiﬁcant difference
in the levels of expression in the epithelium, stroma and blood
vessels. Comparison of staining intensities in TAM exposed pre
and postmenopausal endometrium, revealed a signiﬁcant differ-
ence, with the premenopausal tissue exhibiting a signiﬁcantly
higher level of expression in the stroma (P=0.033).
Vascular density and endothelial proliferation index
The vascular density of the endometrium was determined through-
out the menstrual cycle by CD 34/Ki-67 double immuno-






























Table 1 Comparison of the level of expression between tamoxifen
exposed endometrium and control endometrium in pre- and
postmenopausal endometrium
Angiogenic factor Premenopausal Postmenopausal
aFGF Epithelium (+) P=0.001 Epithelium (=)
Stroma (+) P=0.0097 Stroma (=)
Endothelium (+) P=0.0117 Endothelium (=)
bFGF Epithelium (=) Epithelium (+)
Stroma (+) P=0.024 Stroma (=)
Endothelium (=) Endothelium (=)
TP Epithelium (=) Epithelium (=)
Stroma (=) Stroma (=)
Endothelium (=) Endothelium (=)
VEGF Epithelium (=) Epithelium (=)
Stroma (7) Stroma (=)
Endothelium (7) Endothelium (=)
ADM Epithelium (=) Epithelium (=)
Stroma (+) P=0.033 Stroma (=)
Endothelium (=) Endothelium (=)
(+) expression level increased in tamoxifen exposed tissue; (=) expression level
equal in tamoxifen exposed tissue and control samples; (7) expression level
reduced in tamoxifen exposed tissue.
Tamoxifen and endometrial angiogenesis
S Hague et al
764
British Journal of Cancer (2002) 86(5), 761–767 ã 2002 Cancer Research UKof the endometrium did not change signiﬁcantly during the
menstrual cycle (see Figure 3). In premenopausal women, tamoxi-
fen exposure signiﬁcantly increased the vascular density (P=0.0018
). CD 34/Ki-67 staining of the endometrium to quantify the
endothelial proliferation index, revealed that endothelial prolifera-
tion did not signiﬁcantly alter across the menstrual cycle. The
endothelial proliferation index in the premenopausal TAM group
was lower than that in the controls but the difference was not
signiﬁcant. The endothelial proliferation index in the post meno-
pausal TAM group was higher than in the controls but again the
difference was not signiﬁcant.
DISCUSSION
The side effects of TAM on the endometrium are thought to largely
stem from the agonistic activity of the drug within this tissue.
Adverse effects of TAM on the endometrium include hyperplasia,
malignancy and uterine bleeding all of which involve angiogenesis.
We have examined the expression of a number of well character-
ized angiogenic factors in the endometrium of pre- and
postmenopausal women receiving TAM therapy, namely aFGF,
bFGF, TP, VEGF and ADM. Apart from ADM (Zhao et al,
1998), previous studies have mainly examined carcinoma lines or
rodent uteri but not human tissues and not in relation to meno-
pausal status. From the work described here, it appears TAM is
capable of modulating the expression of these angiogenic factors,
both in terms of the expression level and proﬁle with aFGF, bFGF
and ADM being upregulated especially in premenopausal tissue.
The effect of TAM exposure on aFGF has only been previously
examined in the Ishikawa endometrial cancer cell line where it
inhibits upregulation by oestradiol (Fujimoto et al, 1997). For
bFGF, previous data are again limited to the Ishikawa endometrial
cancer cell line where TAM inhibits its upregulation by oestradiol
(Fujimoto et al, 1997).
Alteration in the pattern of expression by TAM was also observed
with TP, with cyclical expression being replaced by a constant level in
premenopausal tissues. Changes in the level of TP expression were
not apparent when comparing control and TAM groups. Previous
studies by ourselves have found that TP is not expressed in human
endometrial adenocarcinomas (Zhang et al, 1997). However others
have shown expression (Fujiwaki et al, 1998; Sivridis et al, 1999).
Thus the role of TP in endometrial malignancy unclear.
Previous studies of the effect of TAM exposure on uterine VEGF

































Figure 2 Localisation of bFGF in the endometrium using a streptABC peroxidase method. Positive staining appears in brown. (A) Expression in the
normal endometrium (proliferative), (B) bFGF expression in the epithelium and stroma of the post menopausal endometrium, (C) increased expression
in the epithelium and stroma of the premenopausal tamoxifen (proliferative) samples, (D) increased expression in the epithelium and stroma of the post
menopausal tamoxifen exposed endometrium (Magniﬁcation 6400).
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et al, 1996).
ADM expression in response to TAM exposure appeared to be
altered only in the premenopausal tissue studied, with expression
being increased in the stroma. These ﬁndings concur with our
previous results (Zhao et al, 1998).
Increased expression of a number of angiogenic factors has
previously been documented in endometrial hyperplasias and carci-
nomas, including the overexpression of bFGF and VEGF in
hyperplasia and adenocarcinoma (Gold et al, 1994; Doldi et al,
1996; Zhang et al, 1998). Adrenomedullin is increasingly being
regarded as a signiﬁcant factor in angiogenesis and tumour growth
(Oehler et al, 2001). Indeed it has been demonstrated to be upre-
gulated in a number of distinct tumour types (Hinson et al, 2000).
The upregulation of several angiogenic factors in non hyperplas-
tic TAM exposed endometrium, supports the notion that it induces
angiogenesis in the absence of neoplasia. The mechanism by which
TAM may increase aFGF, bFGF and ADM expression is presently
unknown. However the presence of an AP-1 site in the promoters
of aFGF, bFGF and ADM (Ishimitsu et al, 1994; Erdos et al, 1995;
Payson et al, 1998), provides a possible mechanism for the TAM
induction of these factors, as it has been demonstrated that TAM
is able to initiate gene transcription via an AP-1 site (Webb et
al, 1995). None of these factors have oestrogen response elements.
Increased and malignant cell growth leads to a limited vascular
supply and consequently to hypoxia. Both ADM and bFGF are
known to be upregulated by hypoxia (Cormier-Regard et al,
1998; Nakayama et al, 1998; Le and Corry, 1999; Nguyen and Clay-
comb, 1999; Garayoa et al, 2000). TAM has been shown to induce
hypoxia in MCF-7 xenografts (Evans et al, 1997). The induction of
ADM and bFGF by hypoxia is under the control of the hypoxia
inducible transcription factor-1 (Hif). Thus increased endothelial
cell proliferation in response to TAM therapy, may be mediated
by bFGF and ADM induced via Hif stabilization.
The vascular density and endothelial proliferative index were unal-
tered throughout the menstrual cycle in the endometrium. This
concurs with previous studies (Rees et al, 1984; Hickey et al, 1996;
Hague et al, 2000). Vascular density correlated with the proliferative
index. The vessel density in the TAM exposed tissues was signiﬁcantly
greater in the premenopausal (P=0.0018) but not the postmenopau-
sal samples. These ﬁndings concur with the upregulation of aFGF,
bFGF and ADM in premenopausal tissue. Increased vascular density
in premenopausal tamoxifen exposed endometrium is an important
consideration for premenopausal women using TAM as a chemopre-
ventative agent, especially since the trial results have been divergent
(Fisher et al, 1998; Powles et al, 1998; Veronesi et al, 1998). Our
results, suggest these women may be at an increased risk of abnormal
endometrial angiogenesis. The endothelial proliferation index as
determined by CD34/Ki-67 double immunohistochemistry failed to
detect a signiﬁcant difference in the endothelial proliferation rates
both in the pre- and postmenopausal groups analyzed. The dichoto-
my between the increased vascular density and the lack of effect on
endothelial proliferation may be explained by the fact that the women
had been receiving TAM for over 1 year and that stimulation of
endothelial growth may be an early event.
The absence of a direct effect of TAM on endothelial prolifera-
tion in the endometrium is in contrast to the effects of TAM on
the breast where it has been found to be anti-angiogenic in respon-
sive breast tumours (Gagliardi et al, 1996). This may be accounted
for by TAM behaving as an agonist in the endometrium and an
antagonist in responsive breast tumours.
In conclusion, the present study demonstrates the upregulation
of several angiogenic factors mainly in premenopausal human
endometrium in response to TAM therapy. Further, in premeno-
pausal tissue examined, there was also an increase in vascular
density. These results support the notion that TAM exposure
stimulates endometrial angiogenesis in the absence of endometrial
neoplastic change.
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Figure 3 Comparison of the endothelial cell proliferation index and the vascular density between the premenopausal control (n=30) and tamoxifen
(n=8) group and the postmenopausal control (n=10) and tamoxifen group (n=13) (*Indicates a signiﬁcant P value of less than 0.005).
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